Downstream Effectors of ILK in Cisplatin-Resistant Ovarian Cancer

Despite good responses to first-line treatment with platinum-based combination chemotherapy, most ovarian cancer patients will relapse and eventually develop platinum-resistant disease with poor prognosis. Although reports suggest that integrin-linked kinase (ILK) is a potential target for ovarian c...

Descripción completa

Detalles Bibliográficos
Autores principales: Reyes-González, Jeyshka M., Quiñones-Díaz, Blanca I., Santana, Yasmarie, Báez-Vega, Perla M., Soto, Daniel, Valiyeva, Fatima, Marcos-Martínez, María J., Fernández-de Thomas, Ricardo J., Vivas-Mejía, Pablo E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226328/
https://www.ncbi.nlm.nih.gov/pubmed/32260415
http://dx.doi.org/10.3390/cancers12040880

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226328/
https://www.ncbi.nlm.nih.gov/pubmed/32260415
http://dx.doi.org/10.3390/cancers12040880

Ejemplares similares